Opendata, web and dolomites

MetaTox-HS

Advanced Solutions for High Sensitivity Metabolism and Toxicity Assays

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MetaTox-HS project word cloud

Explore the words cloud of the MetaTox-HS project. It provides you a very rough idea of what is the project "MetaTox-HS" about.

proof    standard    instrumentation    prototyped    reg    contract    scientific    luxcel    uhs    verification    boost    completes    mitoxpress    sole    full    plate    hs    dominated    ltd    nanosensor    platform    bench    innovative    cell    turnover    metatox    engineering    fluorescence    submitted    made    2023    expensive    previously    opportunity    capex    5m    vitro    demonstrated    academia    translate    labs    revenue    kits    criteria    jobs    passing    industry    either    instruments    models    ambition    secures    biosciences    serious    14    plan    creation    review    commercial    challenger    tests    businesses    oct    est    disease    readiness    party    scientists    lux       microfabrication    few    highlights    laboratory    flexible    manufacturing    job    consolidating    toxicity    accessible    doxycheck    metabolism    polymer    business    critical    components    vivo    write    global    16    requirement    3bn    market    final    enormous    320m    pharmaceutical    sub    clear    performance    stages    3rd    cum    bedside    position    drug    trade    re    electronic    scoring    innovation    13    pilot    solution    beneficiary    reader    synergy    consumable   

Project "MetaTox-HS" data sheet

The following table provides information about the project.

Coordinator
LUXCEL BIOSCIENCES LTD 

Organization address
address: BIOTRANSFER UNIT SUITE 3-32 BIOL
city: Cork
postcode: T12
website: www.luxcel.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.agilent.com/en/metatox-hs
 Total cost 1˙469˙333 €
 EC max contribution 1˙028˙533 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LUXCEL BIOSCIENCES LTD IE (Cork) coordinator 1˙028˙533.00

Map

 Project objective

'Drug failure and high development cost (est. €2.3bn/new drug) has driven enormous growth in market need for scientific tests and models of disease, for researchers in academia, institutions and the pharmaceutical industry, that better translate from the bench (in vitro) to the bedside (in vivo). Critical tests are either not available, or only available on a few large, expensive dedicated instruments.

Luxcel Biosciences Ltd (LUX) has prototyped innovation that can now bring these high performance tests, to all laboratory scientists, for use on standard laboratory instrumentation already available in est. 20,000 labs (fluorescence plate reader), without requirement for CapEx.

LUX’s business innovation solution is a platform of low cost, flexible, easy to use and accessible in vitro cell metabolism and toxicity test kits and consumable products (MitoXpress UHS® and dOxycheck™) made possible through innovative synergy of LUX’s fluorescence nanosensor technology, together with advanced polymer microfabrication and electronic engineering.

MetaTox-HS project, completes the final stages of development, verification, pilot process and manufacturing readiness, together with dissemination and exploitation activities, to bring the full product solution to market and secures EU based revenue and job creation; 13 new jobs and €14.5m cum turnover by 2023, consolidating LUXCEL’s EU position (2 YR), and ambition to become a serious #2 challenger in this est. €320m accessible US and global market (5 YR), currently dominated by US businesses.

Proposal previously submitted Oct ’16, scoring highly, passing all three criteria. Following a full commercial review LUXCEL has taken a sole beneficiary role, with key enabling technology provided through 3rd party sub-contract. A full re-write highlights: clear product components, demonstrated proof-of-concept, well-defined market opportunity and strong commercial plan to boost growth. '

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "METATOX-HS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "METATOX-HS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

NAS (2018)

Nexilis augmentation system

Read More  

SHN (2017)

Universal Smart Hypodermic Needle for preventing reuse and accidental pricks

Read More